ESC 2026: ESC 2026: Head-to-head study compares inclisiran and bempedoic acid
Inclisiran outperformed bempedoic acid in LDL-C lowering and target attainment, supporting differentiation in high-risk patients.
Inclisiran outperformed bempedoic acid in LDL-C lowering and target attainment, supporting differentiation in high-risk patients.